Drug Profile
MK 0557
Alternative Names: MK-0557Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Obesity therapies
- Mechanism of Action Neuropeptide Y5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders; Obesity